Acadia Pharmaceuticals Beats Expectations in Q2
It's been an interesting month for Acadia Pharmaceuticals (NASDAQ: ACAD). The biotech announced disappointing results last week from a late-stage study of Nuplazid in treating schizophrenia patients with persistent inadequate response to their current antipsychotic therapy. Acadia's shares tanked, only to make a strong rebound in recent days.
The company's second-quarter results announced after the market closed on Wednesday might add fuel to the fire of that rebound. Here's what you need to know about Acadia's Q2 update.
Image source: Getty Images.
Quelle Fool.com
